Ultragenyx to Sell Priority Review Voucher for $203 Million
Ultragenyx Pharmaceutical said it is selling a rare pediatric disease priority review voucher for $203 million.
Ultragenyx Pharmaceutical said it is selling a rare pediatric disease priority review voucher for $203 million. The company said it received the PRV when the Food and Drug Administration approved Fayuvi rebisufligene etisparvovec-hopf, a treatment for mucopolysaccharido…